Navigation Links
Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
Date:8/9/2012

NEWARK, N.J. and SIENA, Italy, Aug. 9, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A today announced that they have entered into a collaboration agreement under which the companies will explore feasibility and best uses of adding actinium 225 as a payload to Philogen's L19 antibody constructs.  In the approach known as antiangiogenesis, L19 targets newly formed blood vessels that allow cancers to grow.

Antiangiogenesis is a successful approach to treating numerous cancer types.  Currently approved antiangiogenesis drugs act mostly by interfering with the signaling pathway used by cancer cells to stimulate growth of blood vessels.  In most cases, cancer cells eventually find alternative ways to spur blood vessels growth.  In contrast, Philogen's L19 targets adhesion molecules that anchor blood vessel cells which makes it less susceptible to cancer controlled pathways.  Depending on the architecture of vasculature and its proximity to cancer stem cells, actinium 225 could potentially offer an effective combination of properties tailor made for certain cancer types. 

"We believe that this program has a significant potential that could potentially be leveraged in a number of cancer indications," said Duccio Neri, Co-founder and CEO of Philogen S.p.A. and Dragan Cicic, MD, CEO of Actinium Pharmaceuticals.  "We have followed each company's work for years and are very pleased that we now have an opportunity to collaborate on Philogen's novel approach to the field of antiangiogenesis by extending into an alpha emitter approach using the powerful radioisotope actinium."

About L19

L19 is Philogen's proprietary monoclonal antibody platform that targets certain isoforms of fibronectin, an adhesion molecule necessary for growth of cancer blood vessels.  Philogen has developed several formats of the L19 antibody as well as several antibody-payload combinations to
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
2. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
3. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
4. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2012 Results
7. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
8. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
9. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
11. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... This evening, Novo Nordisk awarded sponsorships totaling $100,000 to ... people living with type 2 diabetes on how to ... long-term diabetes related complications. The sponsorships are part of ... promote enduring, sustainable change for people living with diabetes. ...
... Cadence Pharmaceuticals, Inc. (NASDAQ: CADX ), ... proprietary product candidates principally for use in the hospital ... corporate overview at the following investment conferences: , ... , Wednesday, September 7, 2011Time:   , 1:30pm Eastern ...
Cached Medicine Technology:Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011 2
(Date:3/27/2015)... USA (PRWEB) March 27, 2015 According ... rates of newborns born with Neonatal Abstinence Syndrome (NAS) ... NAS will undergo the painful withdrawal process for a ... body tremors, excessive crying, diarrhea, and vomiting. The condition ... undergoing drug and alcohol addiction treatment (and employing medically ...
(Date:3/27/2015)... London, UK (PRWEB) March 27, 2015 ... that it has appointed Sean Fitzgerald, a former technology ... Chief Operating Officer and Interim Chief Financial Officer. , ... leading education technology innovator, EverFi, backed by Amazon founder ... Twitter founder Evan Williams. Prior to EverFi, he was ...
(Date:3/27/2015)... 2015 SMI (Silicon Microstructures, Inc.), a ... launched the SM1120 MEMS based ultra-miniature pressure sensor designed ... profile at only 220um x 75um provides ample space ... locations. With industry leading in vivo drift performance ... a broad operating pressure range from 0 to 1,100 ...
(Date:3/27/2015)... Diego, CA (PRWEB) March 27, 2015 ... launch its Protect Our Children (POC) NOW! vitamin D ... the Medical University of South Carolina (MUSC), and will ... will be available at no cost to a minimum ... gestation who live within these two service areas. The ...
(Date:3/27/2015)... 2015 California’s ongoing worst ever drought, ... and the United States Northeast, are both manifestations of ... atmosphere is creating changes in the atmosphere’s “energy balance,” ... former NASA researcher, speaking on the Sharon Kleyne Hour™ ... only a warmer and dryer global climate but also ...
Breaking Medicine News(10 mins):Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3
... of two drugs delays disease progression for patients with ... Phase III "ATLAS" trial were presented today by Dr. ... the American Society of Clinical Oncology Annual Meeting. ... whether adding erlotinib (Tarceva), a targeted agent, to maintenance ...
... movers can help reduce risk of serious injury , , SATURDAY, ... movers can help you reduce the risk of injury the ... 20 men who carried a load on a treadmill so ... back, abdomen and forearms. , The study found that carrying ...
... in Heart Failure (HF) syndrome either in stable chronic ... are used to diagnose disease risk, to predict outcome ... a press conference at Heart Failure 2009 in Nice, ... of Cardiology, presented these new findings, namely: , ...
... accessible mini-van and will give it away to a deserving family or ... to ensure this message reaches any family or organization that would benefit ... ... 30, 2009 -- Hyundai of Tempe has acquired a wheelchair ...
... Austin, M.D., founder, Executive Chairman and Chief Medical ... an airplane accident on May 29th, 2009. According ... Sheriff,s Office, his private plane, a Storch two-seater, ... legacy includes leading Arcadian Management Services, a provider ...
... Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that ... Thursday, August 27, 2009, in Rockville, Maryland. The record ... Only stockholders of record at the close of business ... any adjournment thereof. Vanda anticipates mailing its proxy statement ...
Cached Medicine News:Health News:Study shows drug combination improves outcome for advanced non-small cell lung cancer 2Health News:When It Comes to Lifting, the Pros Have Your Back 2Health News:Novel biomarkers in heart failure 2Health News:Hyundai of Tempe to Giveaway Wheelchair Van to Deserving Family 2Health News:Plane Crash Claims Arcadian's Chairman and Founder, John H. Austin M.D. 2
Designed with your input, the ATS Simulus™ flexible annuloplasty ring and band are easy endings to complex mitral valve repairs....
... The unmatched performance of CLS restores ... optimal hemodynamics even when the patient is ... concept of prevention, early detection and restoration ... button) programming and patient management via Home ...
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
Medicine Products: